By Tony Fong

NEW YORK (GenomeWeb News) – Shares of Exact Sciences tumbled 20 percent on Friday, a day after the firm reported validation study results on its stool-based DNA colorectal cancer screening test.

The firm reported that the test had a sensitivity of 64 percent for pre-cancerous lesions and 85 percent for cancerous lesions and a specificity of 88 percent.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: swapping yeast genes with human orthologs to study conservation of function, and more.

Hong Kong is using DNA phenotyping to shame litterers.

A study appearing in Cell suggests some metastatic castration-resistant prostate cancer patients could benefit from PARP inhibitor therapy.

NIH's Francis Collins writes that scientific advances are poised to help populations all over the world, but more scientists are needed to keep the momentum.